Injection
Excipients: sodium chloride, water d/i.
2 ml - colorless glass ampoules (5) - contour plastic cell packaging (1) - cardboard packs.
2 ml - colorless glass ampoules (5) - contour plastic cell packaging (5) - cardboard packs.
Injection transparent, yellowish, practically free of particles.
Excipients: sodium chloride, water d/i.
5 ml - colorless glass ampoules (5) - contour plastic cell packaging (1) - cardboard packs.
5 ml - colorless glass ampoules (5) - contour plastic cell packaging (5) - cardboard packs.
Injection transparent, yellowish, practically free of particles.
Excipients: sodium chloride, water d/i.
10 ml - colorless glass ampoules (5) - contour plastic cell packaging (1) - cardboard packs.
10 ml - colorless glass ampoules (5) - contour plastic cell packaging (5) - cardboard packs.
Excipients: sodium chloride, water d/i.
Solution for infusion (in sodium chloride solution 0.9%) transparent, colorless to slightly yellow.
Excipients: sodium chloride, water d/i.
250 ml - colorless glass bottles (1) - cardboard packs.
Clinical and pharmacological group
A drug that activates tissue metabolism, improves trophism and stimulates the regeneration processpharmachologic effect
An antihypoxant is a hemoderivat, which is obtained through dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons penetrate).
It has a positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to the stabilization of plasma membranes of cells during ischemia and a decrease in the formation of lactates), thus providing an antihypoxic effect.
Actovegin ® increases the concentrations of ATP, ADP, phosphocreatine, as well as amino acids (glutamate, aspartate) and GABA.
The effect of the drug Actovegin ® on the absorption and utilization of oxygen, as well as insulin-like activity with stimulation of glucose transport and oxidation are significant in the treatment of diabetic polyneuropathy.
In patients with diabetes mellitus and diabetic polyneuropathy, Actovegin ® significantly reduces the symptoms of polyneuropathy ( stabbing pain, burning sensation, paresthesia, numbness lower limbs). Sensitivity disorders are objectively reduced and the mental well-being of patients is improved.
The effect of Actovegin begins to appear no later than 30 minutes (10-30 minutes) after parenteral administration and reaches a maximum, on average, after 3 hours (2-6 hours).
Pharmacokinetics
Using pharmacokinetic methods it is impossible to study pharmacokinetic characteristics (absorption, distribution, excretion) active ingredients Actovegin ® drug, since it consists only of physiological components that are usually present in the body.
To date, no decrease in the pharmacological effectiveness of hemoderivatives has been found in patients with altered pharmacokinetics (including hepatic or renal failure, changes in metabolism associated with old age, due to the metabolic characteristics of newborns).
Indications for use of the drug
- metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury);
- peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers);
- diabetic polyneuropathy;
- wound healing (ulcers of various etiologies, trophic disorders /bedsores/, burns, impaired wound healing processes);
— prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy.
Dosage regimen
Injection administered intravenously, intravenously (including as an infusion) and intramuscularly. The infusion rate is about 2 ml/min.
At ischemic stroke 20-50 ml (800-2000 mg) solution for injection is diluted in 200-300 ml of 0.9% sodium chloride solution or 5% dextrose solution and administered intravenously by drip daily for 1 week, followed by 10-20 ml (400 -800 mg) IV drip for 2 weeks and then switching to taking Actovegin ® in tablet form.
At administer intravenously from 5 to 20 ml of solution for injection (200-800 mg/day) daily for 2 weeks, followed by switching to Actovegin ® in tablet form.
At peripheral (arterial and venous) vascular disorders and their consequences administer 20-30 ml (800-1200 mg) of the drug in 200 ml of 0.9% sodium chloride solution or 5% dextrose solution intravenously or intravenously daily; Duration of treatment - 4 weeks.
At diabetic polyneuropathy administer 50 ml (2000 mg) per day intravenously for 3 weeks, followed by switching to taking the drug Actovegin ® in tablet form - 2-3 tablets. 3 times/day for at least 4-5 months.
For wound healing administer 10 ml (400 mg) intravenously or 5 ml (200 mg) intramuscularly daily or 3-4 times a week, depending on the healing process (in addition to local therapy with Actovegin ® in dosage forms for external use).
With the aim of the average dose is 5 ml (200 mg) IV daily during intervals between radiation exposures.
At radiation cystitis 10 ml (400 mg) is administered transurethrally daily in combination with antibiotic therapy. The rate of administration is about 2 ml/min.
The duration of treatment is determined individually, depending on the symptoms and severity of the disease.
Solution for infusion administered intravenously by drip or intravenous injection. The infusion rate is about 2 ml/min.
The duration of treatment is determined individually, depending on the symptoms and severity of the disease.
At ischemic stroke administer 250-500 ml (1000-2000 mg) per day intravenously for 2 weeks, followed by switching to taking the drug Actovegin ® in tablet form.
At metabolic and vascular disorders of the brain at the beginning of treatment - 250-500 ml (1000-2000 mg) per day intravenously for 2 weeks, followed by switching to taking Actovegin ® in tablet form.
At peripheral vascular disorders and their consequences introduce 250 ml (1000 mg) intravenously or intravenously, daily or several times a week, followed by switching to taking Actovegin ® in tablet form.
At diabetic polyneuropathy administer 250 ml (2000 mg; 8 mg/ml) or 500 ml (2000 mg; 4 mg/ml) per day intravenously for 3 weeks, followed by switching to taking the drug Actovegin ® in tablet form - 2-3 tablets. 3 times/day for at least 4-5 months.
For wound healing administer 250 ml (1000 mg) intravenously daily or several times a week, depending on the speed of healing. Maybe joint use with Actovegin in dosage forms for external use.
For prevention and treatment of radiation injuries of the skin and mucous membranes on average, 250 ml (1000 mg) is administered intravenously the day before and daily during radiation therapy, as well as for 2 weeks after its completion, followed by switching to taking the drug Actovegin ® in the form of tablets - 2-3 tablets. 3 times/day for at least 4-5 months.
Side effect
Allergic reactions: skin rash, skin hyperemia, hyperthermia, up to anaphylactic shock.
Contraindications to the use of the drug
- decompensated heart failure;
- pulmonary edema;
- oliguria;
- anuria;
- fluid retention in the body;
— increased sensitivity to the components of the drug;
- increased sensitivity to similar drugs.
WITH caution the drug should be prescribed for hyperchloremia, hypernatremia.
Use of the drug during pregnancy and lactation
The use of the drug during pregnancy did not have any effect negative impact on the mother or fetus, however, if it is necessary to use the drug during pregnancy, the potential risk to the fetus should be taken into account.
Use for renal impairment
WITH caution the drug should be prescribed for oliguria and anuria.
special instructions
Due to the potential development anaphylactic reactions It is recommended to carry out a test (test injection of 2 ml IM) before starting the infusion.
In the case of intramuscular administration, the drug should be administered slowly in an amount of no more than 5 ml.
Actovegin solutions have a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the starting materials used, but this does not affect the effectiveness and tolerability of the drug.
Do not use a solution that is opaque or contains particles.
After opening the ampoule or bottle, the solution cannot be stored.
Overdose
Information on overdose of the drug Actovegin ® is not provided.
Drug interactions
Drug interactions with Actovegin ® have not been established.
However, to avoid possible pharmaceutical incompatibility, it is not recommended to add other medicines to Actovegin infusion solution.
Conditions for dispensing from pharmacies
The drug is available with a prescription.
Storage conditions and periods
The drug should be stored in a place protected from light, out of reach of children, at a temperature not exceeding 25°C. Shelf life - 5 years.
Actovegin is an extract removed from calf blood protein, which also has a stimulating effect on the body. This drug is available in different forms release (gel, injections,) and is used for treatment various kinds diseases, including neuralgic disorders. Most often, during treatment neurological diseases Actovegin solution is used for therapeutic injections.
Actovegin, a drug obtained from an extract from calf blood, has physiological basis, which makes it safe even for children. This drug, which has no serious side effects on the body, is prescribed to all patients for whom the list of its pharmacological properties. The medicine is usually well tolerated.
The composition of the drug includes:
- actively active substance – extract from the blood of calves;
- Excipients, promoting the absorption of various vitamins and microelements, this segment includes: water, sodium chloride.
It is important to know: in some cases, pain may appear when taking the medicine, which is associated with increased secretion, but you should not stop taking the drug. Treatment should be stopped if the pain does not go away and there is no effect from taking the drug.
Pharmacological profile
The components of the Actovegin solution are physiological, so it is not possible to study their pharmacokinetics after ingestion. The medication exerts its effect by enhancing energy metabolism. It accelerates the utilization of oxygen and thus increases resistance to oxygen starvation in tissues human body.
As mentioned earlier, using pharmacokinetic methods it is impossible to study the pharmacokinetic characteristics (absorption, distribution, excretion) of the active components of the drug Actovegin, since it consists only of physiological components that are usually present in the body.
To date, there is no reason to assume a decrease in the pharmacological effect of the drug in patients with disorders physiological functions absorption and excretion of decay products.
With the help of evidence-based medicine, it is known that Actovegin in the form of injections quickly penetrates into circulatory system and the active substance is distributed throughout the body, which explains its rather rapid effect.
Evidence-based medicine
There are many articles on the global web on the topic that there is no direct evidence of the effect of Actovegin injections and therefore it is useless to use it. All evidence for this is based on the same physiological components that haunt many doctors.
But, there is such a branch of medicine as evidence-based medicine, which in practice proves the effectiveness of a particular drug over a certain period of time.
This happened with Actovegin, which has been on the pharmaceutical market for more than 30 years and reviews about it are extremely positive from both patients and leading experts, which means that there is no reason to consider this nootropic drug ineffective.
Indications and contraindications for use
Indications for the use of Actovegin in the form of injections: 
- neuralgic disorders (including,);
- diabetes;
- disturbance of blood supply and metabolism;
- phlebeurysm;
- disturbance of vascular tone.
The medication is also prescribed for faster healing wounds and burns of varying degrees.
Actovegin in ampoules has no contraindications for its use, but it is not recommended to give injections if the patient has an allergic reaction to one of the components of this medication.
Instructions for use
Injections of the drug Actovegin are used intravenously or intramuscularly (depending on the degree and type of the disease). At intravenously, the drug is prescribed in drop or stream form, and before its administration, the drug is dissolved in a sodium chloride solution for faster dissolution when it enters the body. In this case, the daily dosage should not exceed 20 milligrams.
As for intramuscular administration, in this case, first of all, it is necessary to select the required dosage. At first, it ranges from 5 to 10 milligrams per day and, if necessary, it increases by 5 milligrams every week. The injection is administered intravenously without additional treatment with sodium chloride.
Similar nootropic drugs quite often used during complex therapy, including for the treatment of neuralgic diseases.
Overdose and side effects
As practice shows, the drug is well accepted by patients and does not cause side effects. However, in rare cases, anaphylactic and allergic reactions associated with individual intolerance to the drug may occur. In addition, the following side effects sometimes occur when taking Actovegin:
- slight redness of the skin or rash on the body;
- general malaise;
- nausea and vomiting;
- headache and loss of consciousness;
- disruption of the gastrointestinal tract;
- joint pain;
- difficulty breathing, sometimes suffocation caused by stiffness respiratory tract;
- increased sweating;
- stagnation of water in the body;
- due to the stiffness of the respiratory tract, the patient may even have problems swallowing water, food and saliva;
- excessive agitation and activity.
Special instructions for use
The manufacturer did not provide information about additional instructions associated with taking the drug. But most patients note that when diabetes mellitus The patient should take the drug under the supervision of a doctor, as it retains water in the body, which, in turn, harms the body in diabetes.
Compatibility of the drug and alcohol
Actovegin, like many other nootropic medications, is incompatible with alcohol, as this puts unnecessary strain on the liver and kidneys.
In case of impaired renal and liver function
As mentioned above, this drug puts a lot of stress on these two vital organs. Therefore, when treating neuralgic or other diseases, it is worth looking for drugs similar action, which do not put so much strain on the activity of the kidneys and liver.
During pregnancy and lactation
For pregnant women and during lactation, Actovegin should not be taken, as this can affect the woman’s hormonal levels.
Reception by children
Injections are contraindicated for children under 5 years of age, as this nootropic drug has a stimulating effect.
Practical application experience
Doctor's review and reviews of patients who were prescribed Actovegin in ampoules.
Doctor's review
The main effect of Actovegin is to enhance oxygen transport in the circulating blood. Thanks to the natural components that make up this drug, its parenteral administration improves metabolic processes in the tissue cells of the human body due to the active consumption, accumulation, movement and release of oxygen and glucose.
The medication improves blood supply to tissue cells, accelerates the restoration of damaged tissue, and helps the body absorb vital substances and elements.
Actovegin can be administered to a patient:
- Intramuscularly– 5 ml per day, course of treatment – 20 injections.
- Intravenously: in jet injections – 10 ml per day; or a dropper is placed - the drug is diluted in 200 ml of saline or 5% glucose solution. The rate of administration should be no more than 2 ml per minute.
The dosage of Actovegin for infusion depends on the form pathological process, at:
- every week up to 50 ml/day is administered, then for two weeks - up to 20 ml/day;
- – two weeks 10-20 ml/day;
- difficult-to-heal damage to integrity skin – 10-20 ml every other day.
Since childhood, my main problem is weak immunity, which quite often affected my health and I was a sickly child. At the age of 19, I was struck down by a disease that affected the area around the eyes.
I immediately went to see a doctor, and he prescribed me intramuscular Actovegin, and after 2 weeks the disease began to subside, and a month later I completely got rid of it. By the way, the drug also improves immunity.
Anastasia Shpanina, 20 years old
Elements of the Actovegin medical solution can cause allergic reaction. Many patients recommend that if allergy symptoms appear, treatment with the drug is gradually discontinued so as not to aggravate the condition.
As a rule, after the allergic irritation has passed, the attending physician selects a new solution that does not contain various allergens.
Pros and cons based on practical experience
Among the pronounced advantages of the drug, the following should be highlighted: 
- high efficiency;
- small amount side effects;
- in the treatment of neuralgic disorders medical solution has an active sedative and tonic effect;
- wide range of applications.
Cons: there are contraindications, including an allergic reaction.
Purchase and storage
The price of Actovegin solution in ampoules is 1,500 rubles. The solution is stored for no more than 3 months in a cool place protected from the sun. The drug is dispensed at the pharmacy according to a doctor's prescription.
Disorders of metabolic processes in the human body often lead to tissue damage. Such violations are fraught with consequences and can provoke a number of diseases. The drug Actovegin is one of the most common drugs used in various fields of medicine. The drug has the ability to restore damaged cells, improve metabolic processes. The instructions for using the medicine will allow you to familiarize yourself with the drug, but still it can only be taken as prescribed by a doctor.
Dosage form
Actovegin is available in several pharmaceutical forms: injection ampoules, ointment, gel or tablets. In this article we will look at the drug in the form of a solution for intramuscular or intravenous injections. Before purchasing the drug, it is important to pay attention to the dosage.
- 0.4 mg each, package contains 5 ampoules of 10 ml;
- solution of 200 mg, No. 5 ampoules of 5 ml;
- 80 mg each, No. 25 ampoules of 2 ml.
Description and composition
Actovegin is a drug with antihypoxic and antioxidant effects. wide range. The basic principle of action of the drug is based on tissue regeneration. The drug improves blood circulation, provides brain tissue with the necessary amount of oxygen and other useful components. Actovegin can be used in complex treatment many diseases. The drug provides the body with vital components and is often used for the complex treatment of a large number of diseases in adults and children, as well as pregnant women.
The active component of the drug is deproteinized hemoderivative of calf blood 50 mg, as well as auxiliary components, including sodium chloride, water for injection.
Pharmacological group
Actovegin in ampoules activates metabolic processes, increases the transport and accumulation of glucose to the brain. The drug restores the concentration of amino acids, ADP, and stimulates the utilization of glucose. The use of the drug stabilizes plasma membranes, improves energy balance in tissues.
The antihypoxic effect of the drug appears within 30 minutes after parenteral administration and persists for 3 to 6 hours. Actovegin has the ability to heal tissue at the intracellular level and improve blood supply to brain structures. The principle of action of the drug increases tissue resistance and internal organs to oxygen starvation. The broad mechanism of action of the drug allows it to be used in various fields of medicine, but most often this drug is prescribed in neurology and cardiology in the complex treatment of a large number of diseases.
Actovegin is a multicomponent drug that contains various compounds that have a positive effect on the human body. The drug has been on the market for more than 10 years and is often used to treat diseases accompanied by metabolic disorders.
Indications for use
The instructions for the drug contain a fairly large list of diseases and conditions for which the drug can be used. Actovegin injections are often used in the complex treatment of diseases in children and adults.
for adults
Indications for Actovegin injections may include: the following diseases and states:
- hemorrhagic stroke;
- encephalopathy of various etiologies;
- disturbances in the functioning of venous, peripheral or arterial blood;
- ischemic stroke;
- cerebral metabolic disorders;
- traumatic brain injuries;
- angiopathy;
- damage to the cornea of the eye of various etiologies;
- burns up to 3rd degree;
- trophic skin damage;
- wounds that are difficult to treat;
- skin ulcers;
- bedsores.
for children
In pediatrics, Actovegin is most often used in newborns for brain problems. The drug can be used from the first days of a child’s life acute period. The main indication for use of the drug is:
- prenatal;
- TBI during childbirth;
- burns.
Indications for use are postpartum injuries in a child, violation cerebral circulation and other serious conditions.
for pregnant women and during lactation
Actovegin can be used during pregnancy, but with caution and under the strict supervision of a doctor. The drug is considered very safe for the fetus and the woman herself. It is often used for the following conditions:
- disruption of placental blood supply;
- underdevelopment of the placenta;
- diabetes, type I or II;
- arterial hypertonicity;
- Rh factor conflict between the blood of the fetus and mother;
- oxygen deficiency of the placenta and embryo.
Actovegin injections can be prescribed to pregnant women and as a prophylaxis in the presence of a risk of miscarriage or premature birth. At breastfeeding many doctors do not recommend using the drug.
Contraindications
Actovegin is a physiological drug, so the only contraindication for use was an increased reaction of the body.
Applications and dosages
Actovegin solution is intended for intra-arterial, intramuscular, intravenous administration. If necessary, the drug is administered into vascular bed in the form of infusions. Despite the good tolerability of the drug, a sensitivity test must be performed before using it.
For adults
According to the instructions for the drug, Actovegin solution is prescribed individually for each patient, depending on the diagnosis, the patient’s age, and the method of administration.
- At intravenous administration the drug is diluted in a 5% glucose solution or in 0.9% sodium chloride. Daily dose should not exceed 2000 mg per ¼ liter of solution.
- At intramuscular injection the dosage is no more than 5 ml per day.
- Intra-arterial administration of the drug varies from 5 to 20 ml per day.
Treatment with Actovegin ranges from 10 days to several weeks or months.
For children
The daily dose of the drug is calculated as 0.4-0.5 ml per 1 kg of body weight intramuscularly. Treatment with Actovegin significantly increases and improves the prognosis for recovery.
For pregnant women and during lactation
For pregnant women, the dose of the medicine is determined by the doctor individually for each patient.
After using the injections, the effect does not appear so quickly. The positive effect from taking it may appear no earlier than after 1 week and will persist for several months.
Side effects
The drug is well tolerated, but in rare cases, after administration of the drug, symptoms may appear. adverse reactions body:
- anaphylactic reactions;
- pain in the injection area;
- headache;
- dyspeptic symptoms;
- tachycardia;
- rash on the body;
- increased arousal;
- breathing problems;
- difficulty breathing;
The medicine has no toxic effect on the body and is not addictive. If the patient has hypersensitivity to Actovegin, the doctor may prescribe analogues of the drug. The closest analogue of the medicine is.
Interaction with other drugs
The drug is often combined with other medicines. There is no data on drug incompatibility.
Instructions for use
Actovegin instructions for use
Dosage form
Round, biconvex, film-coated, greenish-yellow, shiny tablets.
Compound
1 film-coated tablet contains:
Core: active substance: blood components: deproteinized hemoderivative of calf blood - 200.0 mg in the form of Actovegink granulate* - 345.0 mg, excipients: magnesium stearate - 2.0 mg, talc - 3.0 mg;
Shell: acacia gum - 6.8 mg, mountain glycol wax - 0.1 mg, hypromellose phthalate - 29.45 mg, diethyl phhalate - 11.8 mg, dye quinoline yellow aluminum varnish - 2.0 mg, macrogol-6000 - 2 .95 mg, povidone-K 30 - 1.54 mg, sucrose -52.3 mg, talc - 42.2 mg, titanium dioxide - 0.86 mg.
* Actovegin1* granulate contains: active substance: blood components:
Deproteinized hemoderivative of calf blood - 200.0 mg, excipients: povidone-K 90 - 10.0 mg, microcrystalline cellulose - 135.0 mg.
Pharmacodynamics
Actovegin® is an antihypoxant that has three types of effects: metabolic, neuroprotective and microcirculatory. Actovegin increases the absorption and utilization of oxygen; The phospho-oligosaccharides contained in the drug inositol have a positive effect on the transport and utilization of glucose, which leads to an improvement in the energy metabolism of cells and a decrease in the formation of lactate under conditions
Several ways to implement the neuroprotective mechanism of action of the drug are being considered.
Actovegin prevents the development of apoptosis induced by beta-amyloid peptide (A(325-35).
Actovegin modulates the activity of nuclear factor kappa B (NF-kB), which plays important role in the regulation of apoptosis and inflammation in the central and peripheral nervous system.
Another mechanism of action involves the nuclear enzyme poly(ADP-ribose) polymerase (PARP). PARP plays an important role in the detection and repair of single-stranded DNA damage, but excessive activation of the enzyme can trigger cell death in conditions such as cerebrovascular disease and diabetic polyneuropathy. Actovegin inhibits PARP activity, which leads to functional and morphological improvement in the central and peripheral nervous system.
The positive effects of the drug Actovegin, affecting microcirculation processes and the endothelium, are an increase in the speed of capillary blood flow, a decrease in the pericapillary zone, a decrease in the myogenic tone of precapillary arterioles and capillary sphincters, a decrease in the degree of arteriovenular shunt blood flow with preferential blood circulation in the capillary bed and stimulation of the function of endothelial oxide synthase nitrogen, affecting the microvasculature.
During various studies It was found that the effect of the drug Actovegin occurs no later than 30 minutes after taking it. The maximum effect is observed 3 hours after parenteral and 2-6 hours after oral administration.
Pharmacokinetics
Using pharmacokinetic methods, it is impossible to study the pharmacokinetic parameters of the drug Actovegin, since it consists only of physiological components that are usually present in the body.
Side effects
The frequency of side effects was determined according to the classification of the Council of International Organizations of Medical Sciences (CIOMS): very often (> 1/10); often
(>1/100 to<1/10); нечасто (>1/1000 to<1/100); редко (>1/10000 to<1/1000); очень редко (< 1/10000); не известно (не может быть оценена по имеющимся данным).
Immune system disorders
Rarely: allergic reactions (drug fever, symptoms of shock).
Skin and subcutaneous tissue disorders
Rarely: urticaria, sudden redness.
Selling Features
prescription
Special conditions
Clinical data
In the multicenter, randomized, double-blind, placebo-controlled ARTEMIDA trial (NCT01582854), which examined the therapeutic effect of Actovegin® on cognitive impairment in 503 patients with ischemic stroke, the overall incidence of serious adverse events and death was similar in both treatment groups. Although the incidence of recurrent ischemic strokes was within the expected range in this patient population, there were more cases in the Actovegin group compared to the placebo group, but this difference was not statistically significant. There was no relationship between the incidence of recurrent stroke and the study drug.
Use in pediatric patients
Currently, there is no data on the use of Actovegin in children, so its use in this group of people is not recommended.
Impact on the ability to drive a car and other mechanisms
Not installed.
Indications
As part of complex therapy:
Symptomatic treatment of cognitive impairment, including post-stroke cognitive impairment and dementia.
Symptomatic treatment of peripheral circulatory disorders and their consequences.
Symptomatic treatment of diabetic polyneuropathy (DPN).
Contraindications
Hypersensitivity to the drug Actovegin® and similar drugs or excipients.
Fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency.
Children under 18 years of age.
Carefully
Pregnancy and breastfeeding period.
Use during pregnancy and breastfeeding
Actovegin should be used only in cases where the therapeutic benefit outweighs the potential risk to the fetus or child.
Drug interactions
Currently unknown.
Prices for Actovegin in other cities
Buy Actovegin,Actovegin in St. Petersburg,Actovegin in Novosibirsk,Actovegin in Yekaterinburg,Actovegin in Nizhny Novgorod,Actovegin in Kazan,Actovegin in Chelyabinsk,Actovegin in Omsk,Actovegin in Samara,Actovegin in Rostov-on-Don,Actovegin in Ufa,Dementia
2 tablets 3 times a day (1200 mg/day). The total duration of treatment is 20 weeks. Peripheral circulation disorders and their consequences
1-2 tablets 3 times a day (600 - 1200 mg/day). Duration of treatment is from 4 to 6 weeks.
Diabetic polyneuropathy
2000 mg per day intravenously, 20 infusions with switching to tablet form, 3 tablets 3 times a day (1800 mg/day), duration from 4 to 5 months.
Overdose
According to preclinical studies, Actovegin does not exhibit toxic effects even when the dose is 30-40 times higher than the doses recommended for use in humans. There have been no cases of overdose with Actovegin.Actovegin belongs to the group of antihypoxants, i.e. drugs that help body cells store oxygen and reduce the need for it. The pharmaceutical raw material for the production of Actovegin is calf blood serum extract. By activating the cellular metabolism of oxygen and glucose and optimizing their consumption, the drug significantly increases the energy capabilities of cells and their resistance to oxygen starvation. When using Actovegin, the synthesis of ATP - the main energy "fuel" of the body - increases 18 times. Thus, all energy-consuming processes in cells are intensified (regeneration). At the same time, Actovegin also increases the concentration of the body’s “building materials” - amino acids aspartate, glutamate, gamma-aminobutyric acid, which contributes, for example, to the speedy healing of wounds and other skin damage.
The method of using Actovegin is determined by its release form. Tablets are taken three times a day before meals along with a small amount of water, 1-2 pieces. Duration of treatment is 1-1.5 months. Actovegin solution is injected into a vein, muscle or artery. The initial dose is 10-20 ml per day, then the dose is reduced to 5-10 ml. The duration of treatment depends on the specific disease, for example, for disorders of cerebral circulation and metabolism it is at least a month, for ischemic stroke - 3 weeks, for poorly healing ulcers and burns, they focus mainly on the speed of the healing process.
As for the external forms of release of Actovegin - cream, gel and ointment - in this case the drug is used externally: applied twice a day (this is the established minimum, more often is possible) for at least 12 days. For ulcers, wounds and inflammatory skin diseases, treatment begins with 20% gel and 5% cream, then moves on to 5% ointment (the so-called three-step treatment). In order to prevent bedsores, external forms of Actovegin are rubbed into the skin in the most disadvantaged places in this regard.
When using Actovegin in the form of an injection solution, you should be aware of a number of important circumstances. Thus, when using the drug intramuscularly, it is allowed to administer no more than 5 ml of solution. To prevent allergies, it is recommended to do a test injection (2 ml of solution intramuscularly). No preservatives are used in the production of injectable Actovegin, so injections must be carried out in strict compliance with all aseptic conditions. And most importantly: the opened drug is not stored, and if not all of the solution was used from the open ampoule, then the remaining drug must be disposed of.
Pharmacology
Antihypoxant. Actovegin ® is a hemoderivative, which is obtained through dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass through). It has a positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to the stabilization of plasma membranes of cells during ischemia and a decrease in the formation of lactates), thus having an antihypoxic effect, which begins to manifest itself no later than 30 minutes after parenteral administration and reaches a maximum on average after 3 hours (2-6 hours).
Actovegin ® increases the concentrations of adenosine triphosphate, adenosine diphosphate, phosphocreatine, as well as amino acids - glutamate, aspartate and gamma-aminobutyric acid.
Pharmacokinetics
Using pharmacokinetic methods, it is impossible to study the pharmacokinetic parameters of the drug Actovegin ®, since it consists only of physiological components that are usually present in the body.
To date, a decrease in the pharmacological effect of hemoderivatives has not been found in patients with altered pharmacokinetics (for example, hepatic or renal failure, metabolic changes associated with old age, as well as metabolic characteristics in newborns).
Release form
Solution for infusion (in dextrose solution) is clear, colorless to slightly yellow.
Excipients: dextrose - 7.75 g, sodium chloride - 0.67 g, water for injection - up to 250 ml.
250 ml - colorless glass bottles (1) - cardboard packs.
Dosage
IV drip or IV stream. 250-500 ml per day. The infusion rate should be approximately 2 ml/min. The duration of treatment is 10-20 infusions. Due to the potential for anaphylactic reactions, a test is recommended before starting the infusion.
Metabolic and vascular disorders of the brain: at the beginning - 250-500 ml/day IV for 2 weeks, then 250 ml IV several times a week.
Peripheral vascular disorders and their consequences: 250 ml intravenously or intravenously, daily or several times a week.
Wound healing: 250 ml IV, daily or several times a week depending on the speed of healing. It is possible to use it together with Actovegin ® in the form of medications for topical use.
Prevention and treatment of radiation injuries to the skin and mucous membranes: on average, 250 ml IV the day before and daily during radiation therapy, as well as for 2 weeks after its completion.
Interaction
Currently unknown.
However, in order to avoid possible pharmaceutical incompatibility, it is not recommended to add other drugs to the Actovegin ® infusion solution.
Side effects
Allergic reactions (skin rash, skin hyperemia, hyperthermia) up to anaphylactic shock.
Indications
- metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury);
- peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers);
- wound healing (ulcers of various etiologies, burns, trophic disorders (bedsores), disruption of wound healing processes);
- prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy.
Contraindications
- hypersensitivity to the drug Actovegin ® or similar drugs;
- decompensated heart failure;
- pulmonary edema;
- oliguria, anuria;
- fluid retention in the body.
With caution: hyperchloremia, hypernatremia, diabetes mellitus (1 bottle contains 7.75 g of dextrose).
Features of application
Use during pregnancy and breastfeeding
Use of the drug in pregnant women did not cause negative effects on the mother or fetus. However, when used in pregnant women, the potential risk to the fetus must be taken into account.
Use for renal impairment
Contraindicated in oliguria, anuria.special instructions
With repeated administrations, the water-electrolyte balance of the blood plasma should be monitored.
The infusion solution has a slightly yellowish tint. The color intensity may vary from one batch to another depending on the characteristics of the starting materials used, but this does not adversely affect the activity of the drug or its tolerability.
Do not use a solution that is opaque or contains particles. After opening the bottle, the solution cannot be stored.
